PAX3 and neoplasm: Treatment with YK-4-279 displaces PAX3-FOXO1 from chromatin, represses the expression of critical target genes, and significantly reduces tumor-cell proliferation and invasiveness, highlighting its potential as a targeted therapeutic strategy [111,112].